Biocon firms up plans to list Syngene, licenses Sovaldi
Biocon has outlined definitive plans to take public its research services arm, Syngene, and expects to offload 10-15% from its majority stake via an offer for sale.
Biocon has outlined definitive plans to take public its research services arm, Syngene, and expects to offload 10-15% from its majority stake via an offer for sale.